Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with MIR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Fanwei ^a   Shimakami, Tetsuro ^a   Murai, Kazuhisa ^a   Shirasaki, Takayoshi ^a   Funaki, Masaya ^a   Honda, Masao ^a   Murakami, Seishi ^a   Yi, Minkyung ^b   Tang, Hong ^c   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b University of Texas Medical Branch School of Medicine   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MICRORNA; MIRN122 MICRORNA, HUMAN;

ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HUMANS; MICRORNAS; MUTATION; VIRUS REPLICATION;

EID: 84981738353     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30939     Document Type: Article

References (34)

1. Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. The Lancet. Infectious diseases 5, 558-567, doi: 10.1016/S1473-3099(05)70216-4 (2005)
2. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128, doi: 10.1016/S0140-6736(12)61728-0 (2012)
3. Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801, doi: 10.1038/ nature08463 (2009)
4. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41, 1105-1109, doi: 10.1038/ng.449 (2009)
5. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41, 1100-1104, doi: 10.1038/ng.447 (2009)
6. Welzel, T. M., Dultz, G. & Zeuzem, S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol 61, S98-S107, doi: 10.1016/j.jhep.2014.08.014 (2014)
7. Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M. & Marcellin, P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver international : official journal of the International Association for the Study of the Liver 36 Suppl 1, 47-57, doi: 10.1111/liv.13027 (2016)
8. Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of hepatology 64, 486-504, doi: 10.1016/j.jhep.2015.09.011 (2016)
9. Yoshimi, S. et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 87, 1913-1920, doi: 10.1002/jmv.24255 (2015)
10. Lam, A. M. et al. PSI-7851, a pronucleotide of beta-D-2-deoxy-2-fluoro-2-C-methyluridine monophosphate, is a potent and pangenotype inhibitor of hepatitis C virus replication. Antimicrobial agents and chemotherapy 54, 3187-3196, doi: 10.1128/AAC.00399- 10 (2010)
11. Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrobial agents and chemotherapy 56, 3359-3368, doi: 10.1128/AAC.00054-12 (2012)
12. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581, doi: 10.1126/science.1113329 (2005)
13. Jopling, C. L., Schutz, S. & Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4, 77-85, doi: 10.1016/j.chom.2008.05.013 (2008)
14. Shimakami, T. et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA 109, 941-946, doi: 10.1073/pnas.1112263109 (2012)
15. Li, Y., Yamane, D., Masaki, T. & Lemon, S. M. The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Nature reviews. Microbiology 13, 544-558, doi: 10.1038/nrmicro3506 (2015)
16. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. The New England journal of medicine 368, 1685-1694, doi: 10.1056/NEJMoa1209026 (2013)
17. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201, doi: 10.1126/science.1178178 (2010)
18. Li, Y. P., Gottwein, J. M., Scheel, T. K., Jensen, T. B. & Bukh, J. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5UTR. Proceedings of the National Academy of Sciences of the United States of America 108, 4991-4996, doi: 10.1073/pnas.1016606108 (2011)
19. Jangra, R. K., Yi, M. & Lemon, S. M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol 84, 6615-6625, doi: 10.1128/JVI.00417-10 (2010)
20. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899, doi: 10.1038/nature06783 (2008)
21. Kato, T. et al. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79, 592-596, doi: 10.1128/JVI.79.1.592-596.2005 (2005)
22. Ottosen, S. et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrobial agents and chemotherapy 59, 599-608, doi: 10.1128/AAC.04220-14 (2015)
23. Shimakami, T. et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 140, 667-675, doi: 10.1053/j.gastro.2010.10.056 (2011)
24. Chou, T. C. & Talalay, P. Analysis of combined drug effects: a new look at a very old problem. Trends in Pharmacological Sciences 4, 450-454, doi: 10.1016/0165-6147(83)90490-X (1983)
25. McGivern, D. R. et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147, 453-462 e457, doi: 10.1053/j.gastro.2014.04.021 (2014)
26. Lam, A. M. et al. Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrob Agents Ch 56, 3359-3368, doi: 10.1128/Aac.00054-12 (2012)
27. Svarovskaia, E. S. et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 59, 1666-1674, doi: 10.1093/cid/ciu697 (2014)
28. Israelow, B. et al. Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. Nature communications 5, 5408, doi: 10.1038/ncomms6408 (2014)
29. Jiang, F. et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 479, 423-427, doi: 10.1038/nature10537 (2011)
30. Abbas, Y. M., Pichlmair, A., Gorna, M. W., Superti-Furga, G. & Nagar, B. Structural basis for viral 5-PPP-RNA recognition by human IFIT proteins. Nature 494, 60-64, doi: 10.1038/nature11783 (2013)
31. Sumpter, R. Jr. et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. Journal of virology 79, 2689-2699, doi: 10.1128/JVI.79.5.2689-2699.2005 (2005)
32. Yi, M., Villanueva, R. A., Thomas, D. L., Wakita, T. & Lemon, S. M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103, 2310-2315, doi: 10.1073/pnas.0510727103 (2006)
33. Yi, M. & Lemon, S. M. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J Virol 78, 7904-7915, doi: 10.1128/JVI.78.15.7904-7915.2004 (2004)
34. Honda, M., Shimazaki, T. & Kaneko, S. La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Gastroenterology 128, 449-462 (2005)